NCT04342650View on ClinicalTrials.gov

Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection

PHASE2CompletedINTERVENTIONAL

Enrollment

152

Participants

Timeline

Start Date

April 8, 2020

Primary Completion Date

May 14, 2020

Study Completion Date

June 8, 2020

Conditions

COVID-19SARS-CoV InfectionSevere Acute Respiratory Syndrome (SARS) PneumoniaClinical Trial

Interventions

DRUG

Chloroquine Diphosphate

150mg tablets Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).

DRUG

Placebo oral tablet

150mg placebo tablets

Trial Locations (1)

69093-415

Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus

All Listed Sponsors

lead

Fundação de Medicina Tropical Dr. Heitor Vieira Dourado

OTHER

NCT04342650 - Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection | Biotech Hunter | Biotech Hunter